Hyderabad emerges as an important global hub for Sandoz

Hyderabad: Cementing Hyderabad’s leadership position in the Pharma & GCC space, Sandoz has announced setting up of their Global Capability Centre in Hyderabad which will provide support for their worldwide knowledge services. The center will initially have a workforce of 800 employees, with plans to increase to approximately 1,800 people in the near future.

The announcement was made after leadership of Sandoz – Richard Saynor, CEO (designate), Claire D’Abreau-Hayling, Chief Scientific Officer, Dr. Vanadana Singh, Head Sandoz Development Centre India and Naveen Gullapalli, Head, Novartis Corporate Centre, met with Minister KT Rama Rao today. Jayesh Ranjan, Principal Secretary, Industries & Commerce & IT and Shakthi Nagappan, Director, Life Sciences & Pharma, Government of Telangana also attended the meeting.

Sandoz has a development center in Genome Valley engaged in cutting edge R&D facilities. The team also informed the Minister that they are adding a state-of-the-art laboratory focused on automation in the GV facility. Minister also presented the Hyderabad Pharma City project and highlighted the value proposition for companies like Sandoz. He invited Sandoz to consider setting up a large manufacturing center in Hyderabad.

Minister K.T Rama Rao said that, “I’m delighted that Sandoz has chosen Hyderabad to set-up their global capability center. Hyderabad boasts a top-notch business environment backed by the state, with a strong emphasis on the life sciences industry. Hyderabad is already home to Novartis and has grown into the second largest location for the company, we are looking forward to a similar patronage and association with Sandoz”.

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, their vision is to discover new ways to improve and extend people’s lives. The global portfolio of Sandoz comprises approximately 1,000 molecules, covering all major therapeutic areas, which accounted for 2019 sales of USD 9.7 billion. Their products reach more than 500 million patients globally.

Hyderabad is regarded as the life sciences capital of India and vaccine capital of the world. Hyderabad also has the unique distinction of being home to the largest development centres outside of their headquarters for all of the most valued technology companies including Amazon, Google, Apple, Microsoft, Facebook (Meta), etc.  While the state is driven by its technology affinity and talent pool, support for manufacturing and R&D has also allowed for creation of a growth ecosystem for the Life Sciences and Pharmaceutical segment in a big way. (INN)

Leave a Reply

Your email address will not be published. Required fields are marked *